ESC 365 - undefined undefined undefined

Speaker illustration

undefined undefined undefined

Presentations Articles

Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Towards optimisation of heart failure therapies

Full guideline-directed medical therapy in heart failure patients with reduced ejection fraction: a real-world analysis in older patients with outcome implication

Event: Heart Failure 2025

Topic: Epidemiology, Prognosis, Outcome

Session: Prediction and monitoring in heart failure

Impact of af on sacubitril/valsartan dosing, persistance of treatment and associated outcomes in heart failure patients with reduced ejection fraction

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Acute heart failure - pharmacotherapy 2

Early rhythm control in patients with atrial fibrillation and heart failure: association with long-term outcome in a large european cohort

Event: Heart Failure 2023

Topic: Heart Failure in Atrial Fibrillation

Session: Arrythmias and device therapy in chronic heart failure

Heart failure and cardiovascular outcomes in european patients with atrial fibrillation

Event: ESC Congress 2022

Topic: Imaging

Session: Individual treatment strategies in atrial fibrillation

ABC adherence and impact of optimal medical therapy in heart failure patients with atrial fibrillation

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Chronic heart failure and atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources